Aims/hypothesis Obesity increases the risk of developing type 2 diabetes mellitus, characterised by impaired insulinmediated glucose uptake in peripheral tissues. Liver X receptor (LXR) is a positive regulator of adipocyte glucose transport in murine models and a possible target for diabetes treatment. However, the levels of LXRα are increased in obese adipose tissue in humans. We aimed to investigate the transcriptome of LXR and the role of LXR in the regulation of glucose uptake in primary human adipocytes. Methods The insulin responsiveness of human adipocytes differentiated in vitro was characterised, adipocytes were treated with the LXR agonist GW3965 and global transcriptome profiling was determined by microarray, followed by quantitative RT-PCR (qRT-PCR), western blot and ELISA. Basal and insulin-stimulated glucose uptake was measured and the effect on plasma membrane translocation of glucose transporter 4 (GLUT4) was assayed. Results LXR activation resulted in transcriptional suppression of several insulin signalling genes, such as AKT2, SORBS1 and CAV1, but caused only minor changes (<15%) in microRNA expression. Activation of LXR impaired the plasma membrane translocation of GLUT4, but not the expression of its gene, SLC2A4. LXR activation also diminished insulin-stimulated glucose transport and lipogenesis in adipocytes obtained from overweight individuals. Furthermore, AKT2 expression was reduced in obese adipose tissue, and AKT2 and SORBS1 expression was inversely correlated with BMI and HOMA index. Conclusions/interpretation In contrast to murine models, LXR downregulates insulin-stimulated glucose uptake in human adipocytes from overweight individuals. This could be due to suppression of Akt2, c-Cbl-associated protein and caveolin-1. These findings challenge the idea of LXR as a drug target in the treatment of diabetes.
Introduction
Obesity is associated with an increased risk of type 2 diabetes, which in turn, is characterised by diminished insulin sensitivity in peripheral tissues such as muscle and adipose tissue. Insulin sensitivity in adipocytes has profound effects on whole-body glucose homeostasis [1] and the mechanisms mediating insulin action and glucose uptake are partly elucidated. When insulin binds to the insulin receptor (IR) an intracellular phosphorylation cascade is initiated including insulin receptor substrate (IRS) 1 and 2, phosphatidylinositol 3-kinase, Akt2 and Akt substrate of 160 kDa [2] . A noncanonical pathway consisting of Cbl, C-Cbl-associated protein (CAP) and TC10 has also been shown to be important for efficient insulin signalling [3, 4] . Caveolin 1 (CAV1), a membrane protein and structural constituent of caveolae, has an important role in correct compartmentalisation of proteins involved in the insulin signalling cascade [5] . In adipocytes, impaired insulin action results in diminished translocation of the insulin-sensitive glucose transporter 4 (GLUT4) [6] to the plasma membrane and reduced uptake of glucose into the cell, which contributes to systemic insulin resistance. Basal glucose uptake is independent of insulin signalling and is mediated by GLUT1 [6] . Insulin signalling is fine-tuned by many mechanisms, one of which involves the transcriptional regulation of key genes in the insulin signalling pathway. In addition, certain microRNAs (miRNAs) have emerged as regulators of insulin action [7] .
Liver X receptor (LXR) is a major transcriptional regulator of cholesterol homeostasis and also regulates lipid and glucose metabolism. There are two LXR isoforms, of which LXRβ is expressed in most cell types whereas the expression of LXRα is limited to a few tissues-all lipid-metabolising-including white adipose tissue, liver and muscle. LXR is activated by oxysterols, such as 22-R-hydroxycholesterol (22-R-HC), but its activity can also be stimulated by synthetic ligands such as GW3965 and T0901317. Upon DNA binding, LXR dimerises with the retinoic X receptor (RXR), which is endogenously activated by retinoic acid [8] . Several polymorphisms in the human genes encoding LXR, NR1H3 (encoding LXRα) and NR1H2 (encoding LXRβ), have been associated with obesity and type 2 diabetes [9] [10] [11] . In addition, expression of LXRα is increased in adipose tissue of obese compared with lean women [9] suggesting that LXR might be connected to an unfavourable metabolic phenotype in adipocytes.
In murine models, however, activation of LXR has generally been associated with positive regulation of glucose uptake and increased insulin sensitivity in adipose tissue, suggesting that LXR might be a target for treatment of type 2 diabetes and insulin resistance. Stimulation of LXR increases basal and insulin-stimulated glucose uptake in murine 3T3-L1 cells [12, 13] . An LXR response element has been identified in both murine and human SLC2A4 (GLUT4) promoters [14] and SLC2A4 expression has been shown to be under direct positive LXR regulation in 3T3-L1 adipocytes [13, 15] . However, other studies suggest that the effect of LXR on glucose uptake might be transient or depend on the metabolic status of the adipose tissue [12, 14, 16] .
Studies of the function of LXR in the regulation of insulin sensitivity and lipid storage in human adipocyte cell systems have produced conflicting results. Treatment with the LXR agonist T0901317 has enhanced expression of GLUT4 in human adipocyte-like Simpson-Golabi-Behmel syndrome (SGBS) cells and increased insulin sensitivity in the human liposarcoma cell line LiSa-2 [14, 17, 18] . However, GLUT4 upregulation by LXR was not confirmed by a recent study in SGBS cells [19] and the role of LXR activation in insulin-mediated glucose uptake in primary human adipocytes is still elusive. Although LXR is considered a target for the treatment of type 2 diabetes, data in human fat cells, a possible target for such a therapy, are incomplete. Therefore, we aimed to characterise the function of LXR in human primary adipocytes differentiated in vitro and mature adipocytes purified ex vivo, as these are highly relevant cell systems for investigating potential future human therapies.
Methods
Experimental participants Four different cohorts of participants were used in the study. From the first cohort, subcutaneous adipose tissue was obtained by cosmetic liposuction or plastic surgery and was used to purify stromal vascular fraction (SVF) and mature adipocytes for in vitro experiments.
A second cohort of 137 individuals was used to investigate insulin-stimulated lipogenesis in mature adipocytes.
For analysis of potential correlations between gene expression and clinical variables, a third cohort comprised of 56 obese and non-obese women was used.
A fourth cohort, previously described [20] and consisting of 26 non-obese (BMI<30 kg/m 2 ) and 30 obese (BMI> 30 kg/m 2 ) women, was used to investigate BMI-dependent differences in global gene expression in subcutaneous adipose tissue by microarray analysis.
All four experimental cohorts are described in the electronic supplementary materials (ESM) Methods and ESM Table 1 . The study was approved by the committee on ethics at Karolinska Institutet and explained in detail to each participant. All participants provided their written informed consent.
Cell cultures Primary human pre-adipocytes for in vitro studies were isolated and differentiated from SVF as described [21, 22] .
Human mesenchymal stem cells (hMSCs) were isolated from adipose tissue, expanded and differentiated in vitro as described [23, 24] .
Mature ex vivo adipocytes were isolated from human adipose tissue as described by Rodbell [25] , and cultured as described in ESM Methods.
Detailed descriptions of the all cell culture protocols can be found in ESM Methods.
Agonist treatment Cells were incubated with the synthetic and highly specific LXR agonist GW3965 [26] , the endogenous LXR and RXR ligands 22-R-HC and 9-cis-retinoic acid (9cRA), respectively (Sigma Aldrich, St Louis, MO, USA), or vehicle (DMSO) at indicated concentrations for 6, 12, 24 or 48 h before complete differentiation (day 12 from induction of differentiation). GW3965 was not toxic at the concentrations used in this study, as assessed by Cell Death Detection ELISA PLUS (Roche, Mannheim, Germany; data not shown).
Affymetrix GeneChip human gene 1.0 ST and miRNA 1.0 array protocols The microarray protocols used for genomewide profiling of mRNA and miRNA expression are described in detail in ESM Methods.
Quantitative real-time RT-PCR Extraction of total RNA, synthesis of cDNA and subsequent quantitative real-time RT-PCR (qRT-PCR) using Taqman specific probes (Applied Biosystems, Foster City, CA, USA) were performed as previously described [27] . We used 18S ribosomal RNA and the gene encoding lowdensity lipoprotein receptor-related protein 10 (LRP10) as references. ATP-binding cassette sub-family G member 1 is known to be strongly induced by LXR [28] and was therefore used as positive control for efficient LXR agonist treatment (ABCG1 mRNA induction in three different adipocyte models is shown in ESM Fig. 1 ). Calculations of relative mRNA expression were performed according to the comparative 2 −ΔΔC t method of Livak and Schmittgen [29] .
Western blot Cells were lysed and protein expression was determined using western blot as previously described [27] . β-Actin was used as reference for whole-cell lysates and integrin β1 for subcellular-fractionation lysates. [30] . At the micromolar concentrations of glucose used in this experimental setting, glucose transport is the rate-limiting step for lipogenesis in human fat cells, as discussed previously [31] . Lipogenesis in isolated mature human adipocytes was assessed as described [30] , and a detailed protocol of the assay is also included in ESM Methods. Even in these experimental settings, efficiency of glucose transport was the limiting step in the assay. Glucose incorporation into lipids was expressed per protein amount (cell cultures) or per gram of lipids (mature ex vivo adipocytes).
RNA interference For the protocol and small interfering RNAs (siRNAs) used for downregulation of mRNA expression, see ESM Methods.
Subcellular fractionation For subcellular fractionation experiments, hMSCs were used. hMSCs are suitable for subcellular fractionation where large amounts of cells are required. One 10 cm diameter petri dish was used for each treatment. The cells were incubated in insulin-free medium for 24 h before stimulation using 10 −8 mol/l insulin. Fractionation and analysis of the subcellular distribution of GLUT4 was performed as previously described [32] , with the addition of a centrifugation step (3 min at 600 g) after the initial homogenisation of cells to remove intact cells. The resulting plasma membrane (PM)-containing pellet was lysed and analysed by western blot as described above. PM protein integrin β1 was used as a loading control.
Statistical analysis Variables were tested for normal distribution using the Anderson-Darling test. Student's t test was used for statistical analysis between samples after confirmation of normal distribution. Bars show mean ± SEM. Linear regression was used to analyse correlations. The level of significance was set to 0.05.
Results
Expression profiling of LXR-regulated mRNA and miRNA transcripts in human adipocytes differentiated in vitro To assess the genome-wide effects of LXR activation, global gene expression and miRNA profiling of GW3965-treated SVF-derived adipocytes was performed. Surprisingly, using a false discovery rate of 1%, none of the miRNAs expressed in adipocytes were differentially regulated by LXR by more than 15%. The miRNAs that were significantly regulated, by a change of >10%, are shown in ESM Table 2 . On the other hand, mRNA expression profiling revealed that 364 genes were upregulated and 1,161 downregulated according to significance analysis of microarray (SAM) using an expression cut-off of ≥60 for absolute call. Several metabolic pathways were markedly affected by LXR activation, as analysed using WebGestalt software [33] (http://bioinfo. vanderbilt.edu/webgestalt/) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) database (www.genome.jp/ kegg/, accessed 27 August 2012) (p<0.01; Table 1 ). As expected, activation of LXR affected oxidative phosphorylation and carbohydrate and lipid metabolism as well as peroxisome proliferator-activated receptor γ (PPAR-γ) signalling pathways. Interestingly, LXR stimulation also significantly affected insulin signalling (Table 1) . A closer analysis of the insulin signalling pathway revealed that LXR negatively regulated the expression of IRS1, IRS2, AKT2, SORBS1 and CAV1. While SLC2A1 was upregulated by LXR stimulation, SLC2A4 mRNA levels remained unaltered (Table 2) . Among genes important for de novo lipogenesis previously reported to be enhanced by LXR in hepatocytes and murine cell lines, only SREBF1 was significantly upregulated (Table 3) .
Human adipocytes differentiated in vitro possess insulin responsiveness comparable with that of mature human adipocytes ex vivo To further study the effects of LXR activation on glucose uptake in human adipocytes, we characterised insulin responsiveness in two human primary adipocyte models: adipocytes differentiated in vitro from SVF and adipocytes differentiated from hMSCs that were expanded via several passages. hMSC-derived adipocytes become insulin resistant during in vitro differentiation even when low continuous insulin (1 nmol/l) and glucose (5.5 mmol/l) concentrations are used in the cell culture medium (ESM Fig. 2 ). Therefore we incubated cells in insulin-free medium before acute insulin stimulation. Three hours of incubation were sufficient to restore insulin responsiveness in SVFderived adipocytes and 48 h in insulin-free medium were optimal for insulin responsiveness in hMSC-derived adipocytes (Fig. 1a, b) . This difference could be due to the higher insulin concentrations present in the hMSC differentiation medium. We also investigated the effect of insulin concentration on glucose uptake in these two cell systems. We found that maximal insulin response was reached at concentrations of 10 -9 to 10 −8 mol/l (Fig. 1c, d ). In addition,
we found that insulin responsiveness in SVF-derived in vitro differentiated adipocytes (cohort 1) corresponded well to insulin responsiveness in mature ex vivo adipocytes (cohort 2) (Fig. 1e vs Fig. 1f ). We therefore concluded that our in vitro adipocyte models were suitable for metabolic studies of insulin responsiveness and signalling.
Activation of LXR attenuates insulin-stimulated glucose uptake in human primary adipocytes To determine whether LXR activation affected glucose uptake we stimulated primary human SVF-derived adipocytes, differentiated in vitro, with GW3965 for 24 and 48 h and measured basal and insulinstimulated glucose uptake. While basal glucose uptake was unaltered by LXR activation, insulin-stimulated glucose uptake was significantly inhibited at both time points (Fig. 2a) . To investigate whether LXR activation was dependent on the metabolic status of the adipose tissue, we analysed results from cell cultures obtained from lean (BMI<25 kg/m 2 ) and overweight (BMI>25 kg/m 2 ) donors separately (Fig. 2b) . Interestingly, the insulin-inhibitory effect of LXR agonist treatment was significant only in SVF-derived differentiated adipocytes from overweight donors. To confirm our findings, we determined the rate of glucose incorporation into lipids (lipogenesis) in GW3965-stimulated SVF-derived adipocytes. Lipogenesis was significantly reduced upon LXR agonist treatment (Fig. 2c) . In line with basal glucose uptake, basal lipogenesis was not changed. Lipogenesis was also assessed H]glucose uptake (a-e). Different lengths of starvation were applied for in vitro differentiated SVF-derived (a; n=3; 12 replicates) and hMSC-derived (b; n=1; 5 replicates) adipocytes. Relative insulin effect was calculated as fold over basal glucose uptake at its matching time point. Twelve-and 24-well formats were used. Different insulin concentrations, ranging from 10 −12 to 10 −6 mol/l insulin, were applied for in vitro differentiated SVFderived (c, n=2; 16 replicates) and hMSC-derived (d; n=1; 6 replicates) adipocytes. Ninety-six-well formats were used and relative cpm values are shown. Insulin responsiveness was analysed by glucose transport assay for in vitro differentiated SVF-derived adipocytes (e; n=33) and by lipogenesis assay for primary ex vivo mature adipocytes (f; n=137). *p<0.05, **p<0.01 and ***p<0.001 vs basal . Mean values and statistical differences were calculated for lean and overweight individuals separately. *p<0.05, **p<0.01 and ***p<0.001 vs insulin in human primary mature ex vivo adipocytes obtained from lean and overweight individuals and treated with GW3965 or vehicle for 48 h. Again, in this primary cell system, insulinstimulated lipogenesis was significantly reduced upon LXR activation in adipocytes obtained from overweight individuals (Fig. 2d) . The extent of downregulation in primary mature adipocytes precisely corresponded to the effects in SVFdifferentiated adipocytes (Fig. 2b vs Fig. 2d) . No toxic effects of LXR agonist were observed in mature fat cells under our experimental conditions and the ABCG1 gene was strongly upregulated, which confirms successful LXR activation (ESM Fig. 1 ).
LXR agonist suppresses mRNA expression of AKT2, SORBS1 and CAV1 and their corresponding proteins To confirm LXR regulation of genes mediating insulin signalling and to investigate kinetic effects, we determined the expression of transcripts by qRT-PCR after 6, 12 and 24 h of treatment with GW3965. As predicted by the microarray, mRNA levels of AKT2, SORBS1 and CAV1 were significantly reduced upon LXR activation (Fig. 3a) . However, we were unable to confirm downregulation of IRS1 and IRS2. While SLC2A1 was upregulated, SLC2A4 mRNA was only transiently and moderately induced and returned to baseline after 24 h of stimulation (Fig. 3b) , which was in agreement with mRNA profiling data. In accordance with qRT-PCR data, LXR stimulation attenuated protein expression of AKT, CAP and CAV1, whereas GLUT4 protein remained unaltered and GLUT1 protein expression was not significantly affected (Fig. 3c, d ). RNA interference experiments using siRNA against LXRα and LXRβ isoforms suggested that LXRα is the major isoform regulating AKT2 expression (ESM Fig. 3 ).
Synthetic and endogenous LXR ligands suppress Akt2 expression in human adipocytes
To verify the effect of LXR on expression of Akt2 in detail, we used ELISA specific for this Akt isoform. In addition to GW3965 we also stimulated primary SVF-derived adipocytes, differentiated in vitro, with an endogenous ligand of LXR (22-R-HC) and its dimerisation partner RXR (9cRA) for 48 h. Results demonstrated that Akt2 expression was significantly reduced by both LXR ligands and by the combined treatment with each of them plus 9cRA (Fig. 4a) . However, 9cRA treatment alone had no effect on Akt2 expression. As LXR agonist treatment attenuated insulin-induced glucose uptake already after 24 h of treatment, we investigated Akt2 expression after 24 h as well and at this time point we observed a significant downregulation (ESM Fig. 4 ). In addition, we investigated phosphorylation of Akt2 at ser474 using ELISA. Phosphorylation of Akt2 (p-Akt) was strongly induced by insulin and was attenuated significantly by GW3965 (Fig. 4b) . The ratio of total p-Akt2/Akt2 was not changed upon LXR activation (data not shown) indicating that downregulation of p-Akt2 was mainly mediated via attenuated protein expression. LXR activation inhibits membrane translocation of GLUT4 We further aimed to determine whether the reduction of glucose transport following GW3965 treatment was caused by altered insulin-mediated translocation of GLUT4 to the PM. Subcellular fractionation of PM isolated from vehicletreated and GW3965-stimulated hMSC-derived adipocytes combined with western blot indicated that LXR activation caused a reduction of GLUT4 in the PM fraction compared with vehicle-treated cells (Fig. 5a, b) . The level of reduction corresponded well to the decrease in glucose uptake (Fig. 2a vs Fig. 5b ).
Physiological relevance of expression levels of AKT2, CAP and CAV1 in human adipocytes To prove that attenuated expression of AKT2, CAP and CAV1 has metabolic effects, we performed siRNA knockdowns of these proteins. Suboptimal downregulation of single proteins did not affect glucose uptake in adipocytes differentiated from SVF (data not shown). We hypothesised that simultaneous downregulation of all three proteins mediates the effect of LXR activation and performed combined siRNA treatments against AKT2, CAP and CAV1. Unfortunately, these treatments were toxic to the cells, upregulating lactate dehydrogenase activity by threefold (ESM Fig. 5 ). Therefore, we further investigated whether expression of these genes in human adipose tissue correlates with obesity and insulin resistance in humans. The expression of AKT2, SORBS1 and CAV1 was investigated by qRT-PCR in cohort 3, comprising adipose tissue from 56 individuals and which was well characterised metabolically. The analysis showed that AKT2 and SORBS1 mRNA expression correlated strongly and negatively with BMI and HOMA of insulin resistance (HOMA-IR) [34] (ESM Fig. 6a-d) . When correcting the AKT2-HOMA-IR correlation for variations in BMI, the correlation p value was 0.063. Thus, although HOMA-IR was influenced by BMI, AKT2 levels may also have contributed to variations in HOMA-IR. In addition, AKT2 expression correlated positively with the maximum response to insulin lipogenesis in vitro (ESM Fig. 6e ). By extracting a subset of lean (BMI<25 kg/m 2 ) and obese (BMI>30 kg/m 2 ) individuals from the data set of cohort 3, we found AKT2 mRNA expression to be significantly lower in obese compared with non-obese individuals (obese/lean ratio 0.79, p=0.004). This finding was also confirmed in cohort 4, consisting of 26 non-obese and 30 obese individuals (obese/non-obese ratio 0.88, p=0.03). Unfortunately, all individuals in cohorts 3 and 4 were women and a possible influence of sex was not analysed.
Discussion
In this study, we demonstrate that LXR agonist treatment of human fat cells in vitro causes resistance to insulin's action on glucose metabolism. This is in contrast to earlier findings in murine models [13, 14, 35] and suggests marked species difference in LXR function. We have validated that primary human adipocytes differentiated in vitro are a suitable model to study insulin responsiveness and signalling. In addition, we show that activation of LXR by GW3965 in human adipocytes affects mRNA expression of genes belonging to multiple metabolic pathways, but causes only minor effects on global miRNA expression. The current study demonstrates that LXR activation reduces the expression Relative GLUT4 levels at plasma membrane * NS Fig. 5 Effect of LXR activation on GLUT4 translocation to the PM. Human hMSC-derived adipocytes (n=3) were differentiated in vitro and stimulated with 3.5 μmol/l GW3965 or vehicle for 48 h. Cells were incubated in insulin-free medium for the final 24 h and treated with or without insulin. The PM fraction was isolated using subcellular fractionation assay, upon which GLUT4 content was (a) detected on western blot and (b) quantified. Integrin β1 was used as loading control. *p<0.05 vs insulin of several genes/proteins important for insulin signalling (AKT2, CAP, CAV1), which, in turn, diminishes GLUT4 translocation and attenuates insulin-stimulated glucose uptake upon insulin stimulation. In addition, a negative correlation between mRNA expression of LXR-regulated genes AKT2 and SORBS1 in human adipose tissue and HOMA-IR suggests that these genes may be involved in the development of insulin resistance.
Taken together, these findings suggest that LXR activation in human fat cells impairs the action of insulin by altering the insulin signalling pathway. Even more importantly, this deleterious effect of LXR agonist treatment is more pronounced in adipocytes derived from overweight individuals, which implies that the effects of LXR activation could be BMI dependent even in vivo. This is of considerable clinical interest, since most persons with type 2 diabetes (the target population for LXR agonist treatment) have excess body fat. Furthermore, the similarity of findings using in vitro differentiated fat cells and mature fat cells support the notion of a metabolic memory in adipocytes differentiated in vitro.
In humans, the impact of LXR activation on different biological pathways has previously been studied in hepatocytes [36] and macrophages [37] by microarray analysis. Both these previous studies and our current study indicate that lipid/cholesterol metabolism is one of the major metabolic pathways affected by LXR in human cell systems. Regulation of carbohydrate metabolism appears to be specific to metabolising cells such as hepatocytes and adipocytes. This confirms that the effects of LXR are tissue specific. Moreover, previous expression profiling of LXR-regulated genes in human and murine hepatocytes indicates the species specificity of LXR function [36] . Comparison of our current results with previous data obtained from murine white adipose tissue supports this notion. LXR activation combined with genome-wide mRNA profiling in murine adipose tissue did not demonstrate enrichment of insulin signalling genes among LXR targets [38] . The mechanism for specific regulation of insulin signalling genes in human adipocytes is not known, but could depend on species or cell-type specific transcriptional co-factors, such as CIDEA (cell death-inducing DNA fragmentation factor α-like effector A) [39] .
The effect of LXR stimulation on global miRNA expression has not been studied previously. LXR has been shown to regulate MiR-26a transcriptionally [40] . This miRNA was implicated in LXR-mediated regulation of the ABCA1 and ARL4C genes. Our miRNA profiling did not demonstrate regulation of MiR-26a in human adipocytes. The current data suggest that the effects of LXR activation observed in this study are most likely not mediated via altered expression of miRNA.
Our findings constitute a first contradictive report against the previously published results denoting LXR as a positive regulator of glucose uptake and lipogenesis in adipocytes. Given the previously reported upregulation of GLUT4 expression by LXR in mouse fat cells, it was surprising that GLUT4 expression was on average unaltered by GW3965 in human fat cells. Thus, regulation of GLUT4 expression by LXR might possess a high inter-individual variation, which was not addressed by previous studies using inbred mice strains. Although mRNA levels of SLC2A1 were upregulated by LXR agonist, neither protein level nor basal glucose transport was affected. This could be due to posttranscriptional modifications, translation rate, protein stability or the rather low expression of GLUT1 in adipocytes.
Studies of the genetic origins of insulin resistance in humans have revealed the physiological importance of AKT2 [41] , SORBS1 [42] and CAV1 [43] , where missense mutations or single nucleotide polymorphisms have been shown to affect the prevalence of developing diabetes. Therefore, the correlation of AKT2 and SORBS1 expression with insulin sensitivity may imply a pathophysiological relevance and couple activation of LXR with impaired glucose uptake in adipocytes. Akt2 has been suggested as a central regulator of insulin-mediated glucose uptake in murine adipocytes [44] . However, it has also been proposed that cells possess a large excess of Akt2 protein and that small fluctuations of Akt2 levels are not physiologically important [45] . Our data suggest that the effects of LXR are mediated via combinatorial downregulation of several insulin signalling proteins, such as Akt2, CAP and CAV1, leading to impaired translocation of GLUT4 to the PM. Although our results would be more compelling if we were able to demonstrate the effect of triple gene knockdown, it is technically challenging to achieve efficient and robust knockdown in human fat cells.
The only published clinical phase one study in humans that determined the effects of a non-isoform-specific LXR agonist did not specifically report on the insulin sensitivity in treated individuals [46] . Therefore, the systemic effects of LXR agonists on human insulin sensitivity are still elusive. However, our previous and current studies in human adipocytes suggest that activation of LXR, and LXRα in particular, upregulates lipolysis [47] and attenuates insulinstimulated glucose uptake (current study) -two features connected with an unfavourable metabolic phenotype [1, 48] . It is therefore tempting to speculate that activation of LXR mobilises energy from adipose tissue for usage elsewhere (e.g. in muscle). Indeed, LXR activation has been shown to promote uptake of fatty acids and glucose in primary human myocytes [49, 50] .
In summary, while activation of LXR increases insulin sensitivity in murine systems, it impairs insulin-mediated glucose uptake and metabolism in human fat cells derived from overweight individuals. These effects are mediated mainly by the α isoform via transcriptional suppression of several insulin signalling proteins and ultimately lead to inhibition of GLUT4 translocation. Taken together, our results challenge the concept of LXR as an insulin-sensitising metabolic transcription factor.
